Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-12-31

Clinical Trial Update: Sorafenib. ICORG 06-41, V4 [Phase 2]

View source ↗

Summary

Phase 2 trial ICORG 06-41 evaluating Sorafenib in esophageal and gastric cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sorafenib (Sorafenib)

Snippet

Sponsor: Cancer Trials Ireland | Conditions: Esophageal Cancer, Gastric Cancer | Phase 2 | Status: COMPLETED